Addition of Metastasis-Directed Therapy to Intermittent Hormone Therapy for Oligometastatic Prostate Cancer
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Addition of Metastasis-Directed Therapy to Intermittent Hormone Therapy for Oligometastatic Prostate Cancer
Authors
Keywords
-
Journal
JAMA Oncology
Volume 9, Issue 6, Pages 825
Publisher
American Medical Association (AMA)
Online
2023-04-06
DOI
10.1001/jamaoncol.2023.0161
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Surgical approach does not influence changes in circulating immune cell populations following lung cancer resection
- (2022) Nathaniel Deboever et al. LUNG CANCER
- Management of Patients with Advanced Prostate Cancer: Report from the Advanced Prostate Cancer Consensus Conference 2021
- (2022) Silke Gillessen et al. EUROPEAN UROLOGY
- Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial design
- (2022) Karim Fizazi et al. LANCET
- Radiotherapy in oligometastatic prostate cancer—a pattern of care survey among members of the German Society for Radiation Oncology (DEGRO)
- (2022) Paul Rogowski et al. STRAHLENTHERAPIE UND ONKOLOGIE
- Definitive Local Consolidative Therapy for Oligometastatic Solid Tumors: Results From the Lead-in Phase of the Randomized Basket Trial EXTEND
- (2022) Alexander D. Sherry et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- The oligometastatic spectrum in the era of improved detection and modern systemic therapy
- (2022) Rohan R. Katipally et al. Nature Reviews Clinical Oncology
- Long-Term Outcomes and Genetic Predictors of Response to Metastasis-Directed Therapy Versus Observation in Oligometastatic Prostate Cancer: Analysis of STOMP and ORIOLE Trials
- (2022) Matthew P. Deek et al. JOURNAL OF CLINICAL ONCOLOGY
- Definitive radiotherapy in lieu of systemic therapy for oligometastatic renal cell carcinoma: a single-arm, single-centre, feasibility, phase 2 trial
- (2021) Chad Tang et al. LANCET ONCOLOGY
- Peripheral T cell expansion predicts tumour infiltration and clinical response
- (2020) Thomas D. Wu et al. NATURE
- Outcomes of Observation vs Stereotactic Ablative Radiation for Oligometastatic Prostate Cancer
- (2020) Ryan Phillips et al. JAMA Oncology
- Current topics in radiotherapy for genitourinary cancers: Consensus statements of the Genitourinary Radiation Oncologists of Canada
- (2020) Scott Morgan et al. CUAJ-Canadian Urological Association Journal
- Stereotactic Ablative Radiotherapy for the Comprehensive Treatment of Oligometastatic Cancers: Long-Term Results of the SABR-COMET Phase II Randomized Trial
- (2020) David A. Palma et al. JOURNAL OF CLINICAL ONCOLOGY
- Intermittent versus continuous androgen deprivation therapy for advanced prostate cancer
- (2020) Marlon Perera et al. Nature Reviews Urology
- Radiation induces dynamic changes to the T cell repertoire in renal cell carcinoma patients
- (2020) Jacky Chow et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Model to improve specificity for identification of clinically-relevant expanded T cells in peripheral blood
- (2019) Julie Rytlewski et al. PLoS One
- Local Consolidative Therapy Vs. Maintenance Therapy or Observation for Patients With Oligometastatic Non–Small-Cell Lung Cancer: Long-Term Results of a Multi-Institutional, Phase II, Randomized Study
- (2019) Daniel R. Gomez et al. JOURNAL OF CLINICAL ONCOLOGY
- 18F-fluciclovine PET-CT and 68Ga-PSMA-11 PET-CT in patients with early biochemical recurrence after prostatectomy: a prospective, single-centre, single-arm, comparative imaging trial
- (2019) Jeremie Calais et al. LANCET ONCOLOGY
- Radiation Therapy in the Definitive Management of Oligometastatic Prostate Cancer: The Johns Hopkins Experience
- (2019) Matthew P. Deek et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- Immune and circulating tumor DNA profiling following radiation treatment for oligometastatic NSCLC; translational correlatives from a mature randomized phase II trial
- (2019) Chad Tang et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- Surveillance or Metastasis-Directed Therapy for Oligometastatic Prostate Cancer Recurrence: A Prospective, Randomized, Multicenter Phase II Trial
- (2018) Piet Ost et al. JOURNAL OF CLINICAL ONCOLOGY
- Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial
- (2018) Christopher C Parker et al. LANCET
- Time to abandon single-site irradiation for inducing abscopal effects
- (2018) Eric D. Brooks et al. Nature Reviews Clinical Oncology
- Risks of Serious Toxicities from Intermittent versus Continuous Androgen Deprivation Therapy for Advanced Prostate Cancer: A Population Based Study
- (2017) Huei-Ting Tsai et al. JOURNAL OF UROLOGY
- TCR Repertoire Intratumor Heterogeneity in Localized Lung Adenocarcinomas: An Association with Predicted Neoantigen Heterogeneity and Postsurgical Recurrence
- (2017) Alexandre Reuben et al. Cancer Discovery
- Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial
- (2016) Nicholas D James et al. LANCET
- Timing of androgen-deprivation therapy in patients with prostate cancer with a rising PSA (TROG 03.06 and VCOG PR 01-03 [TOAD]): a randomised, multicentre, non-blinded, phase 3 trial
- (2016) Gillian M Duchesne et al. LANCET ONCOLOGY
- Long-term Follow-up of a Randomized Trial of Radiation With or Without Androgen Deprivation Therapy for Localized Prostate Cancer
- (2015) Anthony V. D’Amico et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Synergistic action of image-guided radiotherapy and androgen deprivation therapy
- (2015) Jennifer A. Locke et al. Nature Reviews Urology
- Treatment of Prostate Cancer With Intermittent Versus Continuous Androgen Deprivation: A Systematic Review of Randomized Trials
- (2013) Saroj Niraula et al. JOURNAL OF CLINICAL ONCOLOGY
- Intermittent versus Continuous Androgen Deprivation in Prostate Cancer
- (2013) Maha Hussain et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Hormone-DNA Repair Circuit Governs the Response to Genotoxic Insult
- (2013) J. F. Goodwin et al. Cancer Discovery
- Androgen Receptor Signaling Regulates DNA Repair in Prostate Cancers
- (2013) W. R. Polkinghorn et al. Cancer Discovery
- Prospective, Observational Study of Pain and Analgesic Prescribing in Medical Oncology Outpatients With Breast, Colorectal, Lung, or Prostate Cancer
- (2012) Michael J. Fisch et al. JOURNAL OF CLINICAL ONCOLOGY
- Intermittent Androgen Suppression for Rising PSA Level after Radiotherapy
- (2012) Juanita M. Crook et al. NEW ENGLAND JOURNAL OF MEDICINE
- Depressive Symptoms and Cortisol Rhythmicity Predict Survival in Patients with Renal Cell Carcinoma: Role of Inflammatory Signaling
- (2012) Lorenzo Cohen et al. PLoS One
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now